Insights

Expansion Opportunity Seqens operates 15 manufacturing sites and 5 R&D centers across Europe, North America and Asia, with recent divestments and lineup changes signaling strategic realignment. This creates openings to offer process optimization, contract manufacturing, and specialty ingredient supply to fill gaps in the reorganized portfolio.

Biobased Innovation The launch of biobased products such as Caprylyl Glycol and AdvensProtect 2-EHG Green indicates a strong sustainability and natural ingredients focus. There is a sales opportunity to propose bio-based, sustainable actives and preservatives for personal care and biotech applications across their portfolio.

Pipelines & Partnerships The upcoming PeptiCode HP-9 hexapeptide-9 initiative and ongoing Personal Care developments point to a demand for biotech-enabled ingredients and tech-enabled development platforms. This suggests cross-sell routes for advanced biotechnologies, analytics, and custom synthesis partnerships.

Digital & Ops Leverage With reliance on SAP FICO, Microsoft Power Apps, AWS and other enterprise tools, Seqens is positioned to benefit from digital engineering services, ERP-driven supply chain optimization, and cloud-based collaboration to streamline procurement, QA, and scale-up for new products.

Strategic Focus & M&A Readiness Recent divestments of Limoges assets and reorganizations in Personal Care and Custom & Specialties indicate a dynamic portfolio realignment. This signals opportunities to engage on divested or realigning product lines, negotiation of continued supply agreements, and potential co-development or licensing deals for high-value actives.

Similar companies to SEQENS

SEQENS Tech Stack

SEQENS uses 8 technology products and services including SAP FICO, Microsoft Power Apps, AutoCAD, and more. Explore SEQENS's tech stack below.

Media & News

SEQENS's Email Address Formats

SEQENS uses at least 3 email formats:
SEQENS Email FormatsExamplePercentage
First.Last@seqens.comJohn.Doe@seqens.com
89%
FLast@seqens.comJDoe@seqens.com
10%
First.L@seqens.comJohn.D@seqens.com
1%

Frequently Asked Questions

What is SEQENS's official website and social media links?

Minus sign iconPlus sign icon
SEQENS's official website is seqens.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does SEQENS generate?

Minus sign iconPlus sign icon
As of October 2026, SEQENS's annual revenue is estimated to be $100M - $250M.

What is SEQENS's NAICS code?

Minus sign iconPlus sign icon
SEQENS's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does SEQENS have currently?

Minus sign iconPlus sign icon
As of October 2026, SEQENS has approximately 1.3K employees across 3 continents, including Europe, Asia and North America. Key team members include Ceo: P. C., Chief Procurement Officer: C. D. and Chief Quality Officer / / Directrice Qualité Groupe - Member Of The Executive Leadership Team (elt): H. M. Explore SEQENS's employee directory with LeadIQ.

What industry does SEQENS belong to?

Minus sign iconPlus sign icon
SEQENS operates in the Pharmaceutical Manufacturing industry.

What technology does SEQENS use?

Minus sign iconPlus sign icon
SEQENS's tech stack includes SAP FICO, Microsoft Power Apps, AutoCAD, Amazon Web Services, Microsoft SharePoint, Shopify, DocuSign and Cisco.

What is SEQENS's email format?

Minus sign iconPlus sign icon
SEQENS's email format typically follows the pattern of First.Last@seqens.com. Find more SEQENS email formats with LeadIQ.

When was SEQENS founded?

Minus sign iconPlus sign icon
SEQENS was founded in 2003.
SEQENS logo

SEQENS

Pharmaceutical ManufacturingAuvergne-Rhône-Alpes, France1001-5000 Employees

Seqens is a global pharmaceutical manufacturing group that develops and produces active ingredients, pharmaceutical intermediates, and specialty ingredients. It operates a network of manufacturing sites and research centers across Europe, North America, and Asia, enabling the development, industrialization, and customization of complex molecules. The company is based in Écully, in the Auvergne-Rhône-Alpes region of France and employs a sizeable international workforce.

Seqens serves pharmaceutical and related industries that require reliable access to advanced ingredients and tailored solutions to bring products to market. In 2026, the group announced the launch of PeptiCode HP-9, reflecting ongoing expansion of its biotechnology portfolio.

Section iconCompany Overview

Website
seqens.com
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2003
Employees
1001-5000

Section iconFunding & Financials

  • $100M - $250M

    SEQENS's revenue is estimated to be in the range of $100M - $250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.